Statement on the use of on the use of tetravalent meningococcal conjugate vaccine A, C, Y, W135 Menveo® - 25 June 2010

As part of the marketing process of the tetravalent conjugate vaccine Menveo® against invasive meningococcal infections, the French High Council of Public Health (Haut Conseil de la santé publique) issued recommendations after consultation with the Technical Committee on Vaccination (Comité Technique de Vaccination) and the Committee on travel-related illness and disease import.

Source: http://www.hcsp.fr/docspdf/avisrapports/hcspa20100625_vaccmeninMenveo.pdf